Please login to the form below

Not currently logged in
Email:
Password:

Merck plans expanded filing for Emend this year

Nausea and vomiting therapy more effective than placebo in 1000-patient trial

Merck and Co - US headquartersMerck & Co's nausea and vomiting therapy Emend is effective in preventing chemotherapy-induced nausea and vomiting (CINV) even when given as a single dose, says a new study.

The 1,000-patient trial revealed that a 150mg injection of neurokinin 1 antagonist Emend (fosaprepitant dimeglumine) was more effective than placebo – both given in combination with oral anti-vomiting drugs ondansetron and dexamethasone – in patients taking moderately-emetogenic chemotherapy (MEC). 

The single-dose regimen is already approved for use in highly-emetogenic chemotherapy (HEC), but Merck says it will now file the results with regulators later this year to broaden Emend's use to include chemotherapy regimens less prone to causing sickness.

All told, 79% of Emend treatment had a complete response – defined as no vomiting or use of additional medications to control nausea in the two to five-day period after chemotherapy - compared to 68.5% of the placebo group.

“Nausea and vomiting remain a significant burden for patients receiving chemotherapy and we look forward to submitting these data for Emend for injection to the FDA,” said Stuart Green, vice president of clinical research at Merck Research Laboratories.

Emend has been a solid product for Merck & Co, with sales last year rising 9% to reach $553m, but is approaching the end of its patent life. The US patent for the oral formulation expires this year, but the injectable remains protected until 2019, according to Merck.

The injectable formulation has been challenged however, with Merck filing a lawsuit in 2012 seeking to block a generic developed by Sandoz, and subsequent suits filed against Accord Healthcare/Intas and Fresenius. 

An automatic 30-month stay on launch of the Sandoz generic comes to an end next month, although the litigation is still moving through the court process. The 30-month stays on the launch of the other generics come to an end next year. 

In the meantime Merck is also facing a challenge on its injectable patent from Apotex, which filed a petition with the US Patent and Trademark Office (USPTO) last December.

Generics aside, competition is building in the CINV sector. Last October the FDA approved Eisai's combination Akynzeo (netupitant and palonosterol), while Tesaro's oral and injectable NK1 antagonist rolapitant was submitted for approval last September.

Article by
Phil Taylor

30th June 2015

From: Sales

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Page & Page

Page & Page is a new kind of marketing communications consultancy. We change beliefs and behaviours to improve health outcomes...

Latest intelligence

Marketing to healthcare professionals – what’s the key ingredient missing from most campaigns?
What do you think is the difference between a campaign developed to win a share-of-mind with consumers and a campaign designed to gain the attention of healthcare professionals?...
What everyone forgets about good organisational change in pharma
Natasha Cowan speaks to Daphne Chung, Head of Organisational Transformation, to learn how she ensures smooth organisational change that takes all stakeholders into account....
Live from Singapore: Oncology in APAC - Evaluating the opportunity for novel therapies
Live webinar: Tuesday 11th December 2018,16:00 SGT / 17:00 JST...

Infographics